- Home
- CTW vs APLT Comparison
CTW vs APLT Comparison
Compare CTW & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTW
- APLT
- Stock Information
- Founded
- CTW 2013
- APLT 2016
- Country
- CTW Japan
- APLT United States
- Employees
- CTW N/A
- APLT N/A
- Industry
- CTW EDP Services
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- CTW Technology
- APLT Health Care
- Exchange
- CTW Nasdaq
- APLT Nasdaq
- Market Cap
- CTW 149.8M
- APLT 178.6M
- IPO Year
- CTW 2025
- APLT 2019
- Fundamental
- Price
- CTW $2.49
- APLT $1.30
- Analyst Decision
- CTW
- APLT Buy
- Analyst Count
- CTW 0
- APLT 5
- Target Price
- CTW N/A
- APLT $4.13
- AVG Volume (30 Days)
- CTW 56.9K
- APLT 5.5M
- Earning Date
- CTW 11-09-2025
- APLT 11-10-2025
- Dividend Yield
- CTW N/A
- APLT N/A
- EPS Growth
- CTW N/A
- APLT N/A
- EPS
- CTW N/A
- APLT N/A
- Revenue
- CTW $76,194,020.00
- APLT $121,000.00
- Revenue This Year
- CTW N/A
- APLT N/A
- Revenue Next Year
- CTW N/A
- APLT $5,935.35
- P/E Ratio
- CTW $58.74
- APLT N/A
- Revenue Growth
- CTW 8.71
- APLT N/A
- 52 Week Low
- CTW $1.71
- APLT $0.30
- 52 Week High
- CTW $4.88
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- CTW N/A
- APLT 62.38
- Support Level
- CTW N/A
- APLT $1.16
- Resistance Level
- CTW N/A
- APLT $1.50
- Average True Range (ATR)
- CTW 0.00
- APLT 0.15
- MACD
- CTW 0.00
- APLT -0.01
- Stochastic Oscillator
- CTW 0.00
- APLT 66.64
About CTW CTW Cayman Class A Ordinary Shares
CTW Cayman is a web-based gaming platform, offering players an immersive digital space through flagship HTML5 platform, G123.jp. The company's primary focus is to serve game developers by providing a comprehensive platform that helps them generate revenue and reach a global audience. The platform offers a diverse selection of free-to-play games inspired by popular Japanese animations and it hosts 28 games, with 9 additional titles in pre-registration.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.